Publications by authors named "Jorge Poo"

Claim this Profile
H
HCV patients with residual fibrosis after DAA treatment re-establish their epigenetic signature after prolonged-release pirfenidone: MINERVA study.
Eira Cerda-Reyes, Ricardo de la Rosa-Bibiano, Ana Sandoval-Rodriguez, Rebeca Rosas-Campos, Aldo Torre, Jorge Luis Poo

Clin Epigenetics· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pirfenidone in post-COVID-19 pulmonary fibrosis.
Raùl H Sansores, Mario Cazzola, Jorge Luis Poo

Eur Respir J· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Noninvasive Evaluation of Prolonged-Release Pirfenidone in Compensated Liver Cirrhosis. ODISEA Study, a Randomised Trial.
Linda E Muñoz-Espinosa, Aldo Torre, Laura Cisneros, Iaarah Montalvo, René Malé, Jorge Luis Poo

Liver Int· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolonged release pirfenidone pharmacokinetics is modified in cirrhosis GENESIS study.
Jorge L Poo, Juan R Aguilar, Raul Bernal-Reyes, Rosalba Alonso-Campero, Frida Gasca

Biomed Pharmacother· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Prolonged-Release Pirfenidone on Renal Function in Septic Acute Kidney Injury Patients: A Double-Blind Placebo-Controlled Clinical Trial.
Jonathan S Chávez-Iñiguez, Jorge L Poo, Miguel Ibarra-Estrada, Leonel García-Benavides, Guillermo Navarro-Blackaller

Int J Nephrol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefits of prolonged-release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis: PROMETEO study.
Jorge Luis Poo, Aldo Torre, Juan Ramón Aguilar-Ramírez, Mauricio Cruz, Luis Mejía-Cuán

Hepatol Int· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges in treating liver fibrosis.
Jorge L Poo, Linda E Muñoz

Ann Hepatol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Epidemiology, physiopathology and diagnosis of pulmonary hypertension in hepatic (PH) cirrhosis].
Misael Uribe, Jaime Morales-Blanhir, Reina Rosas-Romero, Ricardo Campos Cerda, Jorge L Poo

Gac Med Mex· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity.
Jorge Poo, Francisco Galan, Remi Forrat, Betzana Zambrano, Jean Lang

Pediatr Infect Dis J· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioavailability of two oral formulations of a single dose of levofloxacin 500 mg: an open-label, randomized, two-period crossover comparison in healthy Mexican volunteers.
Juan Francisco Galan-Herrera, Jorge Luis Poo, Oscar Rosales-Sanchez, Elvira Fuentes-Fuentes, Lizbeth Cariño

Clin Ther· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of triple therapy with thymalfasin, peginterferon alpha-2a, and ribavirin for the treatment of hispanic chronic HCV nonresponders.
Jorge L Poo, Francisco Sánchez Avila, David Kershenobich, Xochitl García Samper, Rocío Torress-Ibarra

Ann Hepatol· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioavailability of two sublingual formulations of ketorolac tromethamine 30 mg: a randomized, open-label, single-dose, two-period crossover comparison in healthy Mexican adult volunteers.
Juan Francisco Galán-Herrera, Jorge Luis Poo, Jose Alfonso Maya-Barrios, Alberto de Lago, Iván Oliva

Clin Ther· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioavailability of two single-dose oral formulations of omeprazole 20 mg: an open-label, randomized sequence, two-period crossover comparison in healthy Mexican adult volunteers.
Jorge Luis Poo, Juan Francisco Galán, Alejandra Rosete, Alberto de Lago, Iván Oliva

Clin Ther· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatic hematoma and hepatic rupture in pregnancy.
Jorge Luis Poo, Julieta Góngora

Ann Hepatol· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatitis C virus infection and non-Hodgkin's lymphoma: a review and case report of nine patient.
Javier Lizardi-Cervera, Jorge Luis Poo, Karla Romero-Mora, Beatriz Castañeda, Raúl Pichardo-Bahena

Ann Hepatol· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study.
Jorge Luis Poo, Julieta Góngora, Francisco Sánchez-Avila, Sergio Aguilar-Castillo, Guillermo García-Ramos

Ann Hepatol· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).
Marcelo Silva, Jorge Poo, Frank Wagner, Mary Jackson, David Cutler

J Hepatol· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatobiliary diseases in patients with human immunodeficiency virus (HIV) treated with non highly active anti-retroviral therapy: frequency and clinical manifestations.
Javier Lizardi-Cervera, Luis E Soto Ramírez, Jorge Luis Poo, Misael Uribe

Ann Hepatol· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study.
Jorge Luis Poo, F Sánchez-Avila, D Kershenobich, X García-Samper, J Gongora

J Gastroenterol Hepatol· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study.
Jorge Luis Poo, F Sánchez-Avila, D Kershenobich, X García-Samper, J Gongora

J Gastroenterol Hepatol· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Etiology of liver cirrhosis in Mexico.
Nahum Méndez-Sánchez, Juan R Aguilar-Ramírez, Angel Reyes, Margarita Dehesa, Alberto Juórez, Jorge L Poo

Ann Hepatol· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic value of the copper/zinc ratio in hepatocellular carcinoma: a case control study.
Jorge L Poo, Reina Rosas-Romero, Ana C Montemayor, Fernando Isoard, Misael Uribe

J Gastroenterol· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Treatment of patients with recurrence or who do not respond to the first treatment against hepatitis C].
Jorge Luis Poo

Rev Gastroenterol Mex· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis